Evidence map›Paper›PMID 32158785›Full record

ArticleJournal of dentistry (Shiraz, Iran)2020

Biocompatibility of a New Antibacterial Compound and its Effect on the Mechanical Properties of Flowable Dental Composites (Animal Study).

Mehdi Abaszadeh, Meisam Mohammadi, Iman Mohammadzadeh

Abstract read
In one paragraph

Article in Journal of dentistry (Shiraz, Iran), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mehdi AbaszadehPharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.
Meisam MohammadiDept. of Mechanical Engineering, Vali-e-Asr University of Rafsanjan, Rafsanjan, Iran.
Iman MohammadzadehOral and Dental Disease Research Center, Kerman University of Medical Sciences, Kerman, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

statement of the problemRecently, new compound of 3, 5-dimethyl-1-thiocarboxamide pyrazole has been composed with excellent antibacterial property. Biocompatibility and its effects on mechanical properties of dental composites should be considered before clinical use. PURPOSE: The purpose of this study was to evaluate the biocompatibility of 3, 5-dimethyl-1-thiocarboxamide pyrazole as a new antibacterial compound and its effect on the mechanical properties of dental composites. MATERIALS AND

methodIn this experimental study, a new antibacterial compound was synthesis by reaction between Thiosemicarbazide and 2, 4-Pentandione and tested on thirty male albino Wistar rats weighting 200-250gr. Rats were randomly divided into 3 groups of 10, each rat received 3 implants of 3,5-dimethyl-1-thiocarboxamide pyrazole, penicillin v and empty polyethylene tube. A pathologist, who was unaware of types of tested materials and timing, performed the examination of specimens. The depth of cure and flexural strength of resin composite was measured using Iso4049 standard technique. Compressive strength was determined according to Iso9917 standard.

resultsThis compound was biocompatible and there was no significant difference in flexural strength and compressive strength of the composites containing 1% of this compound with the control group (

conclusionThe 3, 5-dimethyl-1-thiocarboxamide pyrazole with a concentration of 1% in flowable composites can be very effective in preventing secondary caries.

Indexed as

Antibacterials agentsBiocompatibilityDental CariesDental MaterialsPyrazoleStreptococcus mutans

Identifiers

PMID32158785
PMCPMC7036352

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.